THE "LANDMARK 50" VIVA PROTOCOL:
ESSENTIAL CARDIOLOGY CLINICAL TRIALS
THE VIVA EVIDENCE FRAMEWORK
To excel in clinical vivas and theory examinations, avoid reciting raw percentage lists. Ground your answers in the PICO structure and articulate the Practice-Changing Lesson. Grouping landmark evidence by domain ensures rapid retrieval during case presentations and bedside grilling.
A. CORONARY ARTERY DISEASE & ACS
1. ISIS-2 (1988): Aspirin & Streptokinase in AMI
* The Lesson: Aspirin administered early in acute myocardial infarction significantly reduces vascular mortality, exhibiting massive additive synergy when combined with fibrinolysis.
* Key Findings: Combined therapy produced a 42% relative reduction in 5-week mortality.
* Viva Q&A:
* Q: What is the primary antiplatelet mechanism?
* A: Irreversible inhibition of cyclooxygenase-1 (COX-1), blocking thromboxane A2 production.
* Q: Did aspirin increase the risk of major bleeding?
* A: There was a slight increase in minor bleeding, but the absolute survival benefit far outweighed the risk.
2. CURE (2001): Clopidogrel with Aspirin in NSTE-ACS
* The Lesson: Dual Antiplatelet Therapy (DAPT) with Clopidogrel and Aspirin is superior to Aspirin monotherapy in Non-ST-Segment Elevation ACS.
* Key Findings: Significant reduction in the composite of CV death, nonfatal MI, or stroke.
* Viva Q&A:
* Q: What was the primary clinical trade-off?
* A: Increased rate of major bleeding without a significant rise in life-threatening or intracranial hemorrhage.
* Q: What was the recommended duration in this landmark trial?
* A: Continued benefit was demonstrated up to 12 months.
3. PLATO (2009): Ticagrelor vs. Clopidogrel in ACS
* The Lesson: Ticagrelor is superior to Clopidogrel across the entire spectrum of ACS, providing an all-cause mortality benefit.
* Key Findings: Significant reduction in ischemic events and vascular mortality without an increase in overall major bleeding.
* Viva Q&A:
* Q: Why does Ticagrelor outperform Clopidogrel?
* A: It is a direct-acting, reversibly binding P2Y12 inhibitor with rapid onset and no dependence on CYP2C19 bioactivation.
* Q: What unique non-bleeding adverse effect requires monitoring?
* A: Self-limiting dyspnea and ventricular pauses, mediated by adenosine reuptake inhibition.
4. TRITON-TIMI 38 (2007): Prasugrel vs. Clopidogrel in ACS Undergoing PCI
* The Lesson: Prasugrel provides more rapid and potent platelet inhibition than Clopidogrel, significantly cutting ischemic recurrences and stent thrombosis at the cost of higher bleeding.
* Key Findings: Significant reduction in primary ischemic composite and stent thrombosis.
* Viva Q&A:
* Q: What are the absolute and relative contraindications?
* A: Prior TIA/Stroke is an absolute contraindication (due to fatal intracranial bleeding). Age ≥75 years and weight <60 kg generally require dose adjustment or alternative agents.
* Q: Which subset derives the greatest net clinical benefit?
* A: Diabetic patients presenting with STEMI undergoing primary PCI.
5. COURAGE (2007): PCI vs. OMT in Chronic Coronary Syndromes (CCS)
* The Lesson: Routine upfront PCI added to Optimal Medical Therapy (OMT) does not reduce all-cause mortality or myocardial infarction in stable CAD.
* Key Findings: PCI provided better initial angina relief, but hard cardiovascular endpoints remained identical to OMT.
* Viva Q&A:
* Q: How did this reshape practice?
* A: Established guideline-directed medical therapy as the mandatory baseline therapy for stable angina, reserving revascularization for refractory symptoms.
6. FAME-2 (2012): FFR-Guided PCI vs. Medical Therapy
* The Lesson: Fractional Flow Reserve (FFR)-guided PCI improves outcomes compared to medical therapy alone when lesions demonstrate true hemodynamic significance (FFR ≤ 0.80).
* Key Findings: FFR-guided PCI significantly reduced urgent revascularization compared to medical therapy alone in ischemia-producing stenosis.
* Viva Q&A:
* Q: Why did FAME-2 succeed where COURAGE showed neutral hard endpoints?
* A: FAME-2 selectively revascularized only functionally significant, ischemia-causing stenoses rather than relying purely on visual angiographic assessment.
7. SYNTAX (2009): CABG vs. PCI in Left Main & Three-Vessel Disease
* The Lesson: Coronary Artery Bypass Grafting (CABG) remains the gold standard for complex multivessel and Left Main disease.
* Key Findings: CABG demonstrated significantly lower rates of major adverse cardiac and cerebrovascular events (MACCE) and repeat revascularization in intermediate and high anatomic complexity.
* Viva Q&A:
* Q: In which anatomical subgroup was PCI non-inferior?
* A: Low SYNTAX score (≤ 22) with isolated Left Main or less complex triple-vessel CAD.
8. FREEDOM (2012): CABG vs. PCI in Diabetic Patients with Multivessel CAD
* The Lesson: CABG is distinctly superior to PCI for diabetic patients with multivessel coronary disease.
* Key Findings: Statistically significant reductions in all-cause mortality and MI with CABG over DES at 5-year follow-up.
* Viva Q&A:
* Q: Why does CABG provide superior survival in diabetics?
* A: Surgical bypass grafts jump past diffuse, vulnerable proximal plaque ruptures, offering collateralized protection to entire myocardial territories.
9. ISAR-REACT 5 (2019): Prasugrel vs. Ticagrelor in ACS
* The Lesson: A routine Prasugrel-based strategy is superior to a Ticagrelor-based strategy in ACS patients scheduled for invasive evaluation.
* Key Findings: Prasugrel significantly reduced the composite of death, MI, or stroke without increasing major bleeding complications.
* Viva Q&A:
* Q: What was the primary driver of this unexpected outcome?
* A: Significant reduction in spontaneous and periprocedural MI with Prasugrel, likely driven by compliance factors (once-daily vs. twice-daily dosing) and drug dynamics.
10. COMPARE (2008/2010): Second-Generation vs. First-Generation DES
* The Lesson: Second-generation thin-strut Drug-Eluting Stents (DES) with biocompatible/fluoropolymer coatings are safer and more effective than first-generation DES.
* Key Findings: Significant reduction in early and late stent thrombosis, target vessel failure, and recurrent myocardial infarction.
* Viva Q&A:
* Q: What engineered features drove these improvements?
* A: Thinner cobalt-chromium struts, superior endothelialization profiles, and non-thrombogenic polymer carriers.
B. HEART FAILURE (HFrEF & HFpEF)
11. CONSENSUS (1987): Enalapril in Severe Heart Failure (NYHA IV)
* The Lesson: Neurohormonal inhibition via ACE inhibitors provides a clear survival benefit in severe, end-stage heart failure.
* Key Findings: Enalapril achieved a 40% relative reduction in 6-month all-cause mortality.
* Viva Q&A:
* Q: What was the historic paradigm shift?
* A: It proved heart failure was a neurohormonal maladaptation requiring blockade, transforming management away from pure symptom-directed diuretics/digoxin.
12. SOLVD-Treatment (1991): ACE Inhibitors in Mild-to-Moderate HFrEF
* The Lesson: ACE inhibitors reduce all-cause mortality and heart failure hospitalizations across broader symptomatic populations with LVEF ≤ 35%.
* Key Findings: Significant 16% reduction in total mortality and substantial reduction in HF admissions.
* Viva Q&A:
* Q: What did the companion SOLVD-Prevention trial demonstrate?
* A: In asymptomatic LV dysfunction, Enalapril delayed progression to overt heart failure and reduced cardiac hospitalizations.
13. RALES (1999): Spironolactone in Severe HFrEF
* The Lesson: Mineralocorticoid receptor antagonism (MRA) added to standard therapy dramatically reduces morbidity and mortality in advanced systolic heart failure.
* Key Findings: 30% relative reduction in all-cause mortality and 35% reduction in HF hospitalizations.
* Viva Q&A:
* Q: What is the primary cardioprotective mechanism of low-dose MRA?
* A: Reversal of aldosterone breakthrough, preventing progressive myocardial interstitial fibrosis and autonomic dysregulation, distinct from its weak diuretic action.
14. EMPHASIS-HF (2011): Eplerenone in Mild Heart Failure (NYHA II)
* The Lesson: MRA therapy provides profound survival and hospitalization benefits even in mildly symptomatic chronic systolic heart failure.
* Key Findings: Early termination due to a 37% reduction in cardiovascular death or HF hospitalization.
* Viva Q&A:
* Q: What clinical advantage does Eplerenone have over Spironolactone?
* A: Higher selectivity for the mineralocorticoid receptor, leading to an extremely low incidence of endocrine side effects like gynecomastia, mastodynia, and erectile dysfunction.
15. CIBIS-II (1999): Bisoprolol in Chronic HFrEF
* The Lesson: Beta-1 selective adrenergic blockade reduces total mortality and sudden cardiac death in symptomatic systolic heart failure.
* Key Findings: 34% reduction in all-cause mortality with Bisoprolol vs. placebo.
* Viva Q&A:
* Q: Why were beta-blockers previously contraindicated?
* A: Their acute negative inotropic effects were feared, until trials proved that long-term up-titration reverses adverse neurohormonal remodeling.
16. COMET (2003): Carvedilol vs. Metoprolol Tartrate
* The Lesson: Carvedilol improves survival to a greater extent than short-acting Metoprolol Tartrate in patients with chronic heart failure.
* Key Findings: Carvedilol significantly extended median survival compared to immediate-release Metoprolol.
* Viva Q&A:
* Q: What pharmacological mechanisms explain this difference?
* A: Comprehensive beta-1, beta-2, and alpha-1 receptor blockade, delivering afterload reduction, potent antioxidant effects, and greater antiarrhythmic coverage.
17. SHIFT (2010): Ivabradine in Symptomatic Systolic HF
* The Lesson: Selective sinus node I_f current inhibition to lower resting heart rate reduces cardiovascular death and HF hospitalizations.
* Key Findings: 18% reduction in the primary composite endpoint, driven primarily by fewer hospital admissions for worsening HF.
* Viva Q&A:
* Q: What is the specific guideline-mandated patient profile?
* A: Chronic HFrEF (LVEF ≤ 35%) in sinus rhythm with resting HR ≥ 70 bpm despite maximally tolerated guideline-directed beta-blocker therapy.
18. PARADIGM-HF (2014): Sacubitril-Valsartan (ARNI) vs. Enalapril
* The Lesson: Dual Angiotensin Receptor-Neprilysin Inhibition is superior to standard ACE inhibition in chronic HFrEF.
* Key Findings: 20% reduction in cardiovascular mortality and HF hospitalizations, accompanied by a 16% reduction in all-cause mortality.
* Viva Q&A:
* Q: What is the physiological synergy of an ARNI?
* A: Neprilysin inhibition prevents the breakdown of beneficial natriuretic peptides (promoting natriuresis, vasodilation, and antifibrotic pathways), while AT1 blockade prevents concurrent RAAS activation.
19. DAPA-HF (2019): Dapagliflozin in HFrEF
* The Lesson: SGLT2 inhibitors represent a foundational, life-saving pillar of guideline-directed medical therapy in HFrEF, independent of diabetic status.
* Key Findings: 26% reduction in worsening heart failure or cardiovascular death in patients with or without Type 2 Diabetes.
* Viva Q&A:
* Q: What cardiac mechanisms explain benefits in non-diabetics?
* A: Improved myocardial energetics, reduction in intraglomerular pressure, reduction in cardiac preload/afterload via osmotic diuresis, and direct myocardial Na+/H+ exchanger-1 inhibition.
20. DELIVER & EMPEROR-Preserved (2021–2022): SGLT2i in HFpEF & HFmrEF
* The Lesson: SGLT2 inhibitors (Dapagliflozin and Empagliflozin) are the first drug classes to show definitive clinical endpoint reductions across preserved and mildly reduced ejection fractions.
* Key Findings: Consistent ~18–21% relative reductions in the composite of cardiovascular death or total heart failure hospitalizations.
* Viva Q&A:
* Q: What was the primary endpoint driver across both trials?
* A: Marked reduction in first and recurrent heart failure hospitalizations across the LVEF spectrum.
21. MADIT-II (2002): Prophylactic ICD in Prior MI with LVEF ≤ 30%
* The Lesson: Primary prevention Implantable Cardioverter-Defibrillators (ICD) reduce all-cause mortality in patients with prior myocardial infarction and advanced LV dysfunction.
* Key Findings: 31% reduction in all-cause mortality in the ICD arm.
* Viva Q&A:
* Q: Why must implantation be delayed at least 40 days post-acute MI?
* A: Post-infarction myocardial stunning may recover, and immediate post-MI ICD placement (proven in DINAMIT) fails to reduce overall mortality due to competing non-arrhythmic death risks.
22. SCD-HeFT (2005): ICD vs. Amiodarone in Mild-to-Moderate HF
* The Lesson: Primary prevention ICD therapy significantly reduces all-cause mortality in both ischemic and non-ischemic cardiomyopathy (NYHA Class II/III, LVEF ≤ 35%).
* Key Findings: ICD therapy yielded a 23% reduction in mortality risk; Amiodarone showed no survival advantage over placebo.
* Viva Q&A:
* Q: Does Amiodarone serve as an acceptable substitute for an ICD in primary prevention?
* A: No; Amiodarone does not confer a mortality benefit in this population and carries long-term end-organ toxicities.
23. MADIT-CRT (2009): CRT-D in Mild Heart Failure with Wide QRS
* The Lesson: Cardiac Resynchronization Therapy with Defibrillator (CRT-D) halts disease progression and reduces adverse clinical events in patients with mild HF symptoms and conduction delay.
* Key Findings: 34% reduction in the composite of all-cause mortality or nonfatal heart failure events, alongside significant reverse LV remodeling.
* Viva Q&A:
* Q: Which conduction morphology derives the absolute greatest benefit?
* A: True Left Bundle Branch Block (LBBB) morphology with QRS duration ≥ 150 ms.
24. STICH & STICHES (2011/2016): CABG in Ischemic Cardiomyopathy
* The Lesson: Surgical revascularization with CABG combined with medical therapy provides a long-term survival advantage over medical therapy alone in patients with ischemic HFrEF (LVEF ≤ 35%).
* Key Findings: While 5-year results showed a trend, the 10-year extended follow-up (STICHES) demonstrated a statistically significant reduction in all-cause and CV mortality with CABG.
* Viva Q&A:
* Q: Did the REVIVED-BCIS2 trial show a similar mortality benefit with PCI in ischemic cardiomyopathy?
* A: No; REVIVED-BCIS2 showed PCI did not reduce all-cause mortality or HF hospitalizations, highlighting the unique durable protection offered by surgical bypass grafting.
C. ATRIAL FIBRILLATION & ANTICOAGULATION
25. RE-LY (2009): Dabigatran vs. Warfarin in Non-Valvular AF
* The Lesson: The direct thrombin inhibitor Dabigatran (150 mg BID) is superior to dose-adjusted Warfarin for stroke prevention with lower intracranial bleeding.
* Key Findings: Significant reduction in stroke and systemic embolism at 150 mg BID, with comparable major bleeding and significant reductions in hemorrhagic stroke.
* Viva Q&A:
* Q: What specific adverse effect was increased with Dabigatran?
* A: Gastrointestinal bleeding and dyspepsia (related to its tartaric acid core).
26. ROCKET-AF (2011): Rivaroxaban vs. Warfarin in High-Risk AF
* The Lesson: Once-daily Factor Xa inhibition with Rivaroxaban is non-inferior to Warfarin for stroke prevention in non-valvular AF.
* Key Findings: Met non-inferiority for stroke/systemic embolism prevention with major reductions in intracranial hemorrhage and fatal bleeding.
* Viva Q&A:
* Q: What characterized this trial cohort compared to other NOAC trials?
* A: Highest mean baseline CHADS2 score (~3.5), confirming efficacy in high-risk populations.
27. ARISTOTLE (2011): Apixaban vs. Warfarin in Atrial Fibrillation
* The Lesson: Apixaban is superior to Warfarin in preventing stroke, reduces major bleeding, and confers an all-cause mortality benefit.
* Key Findings: Statistically superior across three key hierarchical endpoints: stroke/systemic embolism reduction, lower major bleeding, and lower total mortality.
* Viva Q&A:
* Q: What are the three clinical dose-reduction criteria for Apixaban (reducing 5 mg BID to 2.5 mg BID)?
* A: Any two of the following: Age ≥ 80 years, Body Weight ≤ 60 kg, or Serum Creatinine ≥ 1.5 mg/dL.
28. AFFIRM (2002): Rate vs. Rhythm Control in Atrial Fibrillation
* The Lesson: A routine rhythm-control strategy using antiarrhythmic drugs offers no survival advantage over rate control in older AF patients.
* Key Findings: No significant difference in all-cause mortality; rhythm control was associated with increased adverse drug effects and hospitalizations.
* Viva Q&A:
* Q: What critical caveat governs stroke prevention regardless of rate vs. rhythm strategy?
* A: Anticoagulation must be continued based strictly on thromboembolic risk (CHA2DS2-VASc), not on the perceived maintenance of sinus rhythm.
29. RACE II (2010): Lenient vs. Strict Rate Control in Permanent AF
* The Lesson: Lenient rate control is as safe, effective, and non-inferior to strict rate control in asymptomatic permanent AF.
* Key Findings: No significant difference in clinical events, heart failure hospitalizations, or arrhythmias.
* Viva Q&A:
* Q: What are the defined hemodynamic targets for lenient vs. strict control?
* A: Lenient control targets resting HR < 110 bpm; strict control targets resting HR < 80 bpm and moderate exercise HR < 110 bpm.
30. AUGUSTUS (2019): Antithrombotic Regimens in AF + ACS/PCI
* The Lesson: In patients with AF undergoing PCI, a dual-therapy regimen of Apixaban plus a P2Y12 inhibitor without Aspirin markedly reduces bleeding without raising ischemic risk.
* Key Findings: Regimens including Apixaban resulted in significantly less bleeding compared to VKA; omitting Aspirin significantly reduced bleeding without increasing ischemic events.
* Viva Q&A:
* Q: What is the standard contemporary post-PCI discharge regimen for AF?
* A: NOAC plus Clopidogrel (P2Y12 inhibitor), dropping Aspirin immediately post-discharge or within 1 to 7 days peri-procedure.
31. EAST-AFNET 4 (2020): Early Rhythm Control in AF
* The Lesson: Early initiation of rhythm control (via antiarrhythmic drugs or catheter ablation) within 1 year of diagnosis reduces cardiovascular outcomes.
* Key Findings: 21% reduction in cardiovascular death, stroke, or hospitalization for HF/ACS compared to usual care.
* Viva Q&A:
* Q: Why did EAST-AFNET 4 succeed while AFFIRM showed neutrality?
* A: Intervening very early in the disease course prevents progressive structural/electrical atrial remodeling, safer modern antiarrhythmics were used, and anticoagulation was maintained.
D. LIPIDS & HYPERTENSION
32. 4S (1994): Simvastatin in Coronary Heart Disease
* The Lesson: Statin-mediated lipid lowering produces significant reductions in all-cause and cardiovascular mortality in secondary prevention.
* Key Findings: 30% reduction in all-cause mortality and 42% reduction in coronary deaths in high-risk patients.
* Viva Q&A:
* Q: What fundamental concept did 4S cement?
* A: It conclusively proved that cholesterol lowering translates into hard survival benefits, launching the modern statin era.
33. PROVE-IT TIMI 22 (2004): Intensive vs. Moderate Statin Therapy Post-ACS
* The Lesson: High-intensity statin therapy (Atorvastatin 80 mg) provides superior protection against death or major CV events compared to moderate therapy (Pravastatin 40 mg).
* Key Findings: 16% relative risk reduction in major cardiovascular endpoints in the intensive-treatment arm.
* Viva Q&A:
* Q: What is the contemporary guideline target LDL-C level post-ACS (ESC/ACC 2025)?
* A: Target LDL-C < 55 mg/dL AND at least a ≥ 50% reduction frombaseline.
34. JUPITER (2008): Rosuvastatin in Primary Prevention with Elevated hsCRP
The Lesson: Statin therapy reduces major cardiovascular events in patients with low LDL-C who have systemic inflammation (high-sensitivity C-reactive protein ≥ 2.0 mg/L).
Key Findings: 44% reduction in the primary composite endpoint of CV death, stroke, or MI with Rosuvastatin 20 mg.
Viva Q&A:
Q: What biological mechanism did this trial highlight?
A: The pleiotropic, anti-inflammatory, and plaque-stabilizing properties of statins beyond simple lipid reduction.
35. IMPROVE-IT (2015): Ezetimibe Added to Statin Post-ACS
The Lesson: Non-statin lowering of LDL-C via Ezetimibe added to statin therapy incrementally reduces cardiovascular events post-ACS.
Key Findings: Significant reduction in CV death, MI, and stroke, reinforcing the principle that "lower is better" for LDL-C.
Viva Q&A:
Q: What is Ezetimibe’s site and mechanism of action?
A: Selective inhibition of the Niemann-Pick C1-Like 1 (NPC1L1) transporter at the brush border of the small intestine, blocking dietary and biliary cholesterol absorption.
36. FOURIER (2017): Evolocumab (PCSK9 Inhibitor) in Stable Atherosclerotic Disease
The Lesson: PCSK9 monoclonal antibody inhibition added to maximally tolerated statin therapy drastically reduces LDL-C and significantly lowers MACE.
Key Findings: 15% reduction in major cardiovascular events, driving median LDL-C down to 30 mg/dL.
Viva Q&A:
Q: Was there evidence of a clinical floor or safety issue with ultra-low LDL-C (< 20 mg/dL)?
A: No; safety analyses showed no increase in neurocognitive decline, cataract formation, or hemorrhagic stroke at ultra-low achieved LDL levels.
37. ALLHAT (2002): Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
The Lesson: Thiazide-type diuretics are unmatched in preventing one or more major forms of CVD and are foundational first-line agents for hypertension.
Key Findings: Chlorthalidone was superior to Amlodipine and Lisinopril in preventing heart failure hospitalizations.
Viva Q&A:
Q: Why is Chlorthalidone often favored pharmacologically over Hydrochlorothiazide?
A: Significantly longer half-life (40–60 hours vs. 6–12 hours) and proven 24-hour ambulatory BP control.
38. SPRINT (2015): Intensive Blood-Pressure Control
The Lesson: Targeting a systolic blood pressure < 120 mmHg reduces clinical cardiovascular events and all-cause mortality compared to standard targets (< 140 mmHg) in high-risk non-diabetics.
Key Findings: 25% relative risk reduction in primary composite CV events and 27% reduction in all-cause mortality.
Viva Q&A:
Q: What measurement technique is essential when referencing SPRINT data?
A: Automated Office Blood Pressure (AOBP) measurement, which generally records 5–10 mmHg lower than routine manual clinic auscultation.
39. ONTARGET (2008): Telmisartan vs. Ramipril & Combination Therapy
The Lesson: Telmisartan is fully non-inferior to Ramipril in reducing vascular events in high-risk patients; dual ACEi + ARB blockade is harmful.
Key Findings: Equivalent cardiovascular protection with Telmisartan alongside significantly lower rates of cough and angioedema.
Viva Q&A:
Q: What did the combined ACEi + ARB treatment arm reveal?
A: No incremental cardiovascular benefit, but a significant increase in adverse renal failure, hyperkalemia, and syncope.
E. VALVULAR & STRUCTURAL HEART DISEASE
40. PARTNER 1 (2010/2011): TAVI in Inoperable and High-Risk Severe AS
The Lesson: Transcatheter Aortic Valve Implantation (TAVI) is superior to medical therapy (including balloon valvuloplasty) in inoperable severe AS, and non-inferior to SAVR in high-risk patients.
Key Findings: Dramatic 20% absolute reduction in 1-year all-cause mortality compared to standard medical management in inoperable candidates.
Viva Q&A:
Q: What were the predominant periprocedural complications in first-generation TAVI?
A: Paravalvular regurgitation, access-site vascular injury, and early stroke.
41. PARTNER 2 (2016): TAVI vs. SAVR in Intermediate-Risk Aortic Stenosis
The Lesson: TAVI using newer-generation balloon-expandable valves is non-inferior to surgical aortic valve replacement in intermediate surgical risk patients.
Key Findings: Equivalent 2-year rates of all-cause mortality or disabling stroke; transfemoral TAVI achieved statistically superior outcomes to surgery.
Viva Q&A:
Q: What anatomical considerations are evaluated on pre-TAVI CT scans?
A: Annular dimensions/calcification, coronary ostial heights, sinus of Valsalva widths, and iliofemoral vascular minimum luminal diameters.
42. Evolut Low Risk & PARTNER 3 (2019): TAVI in Low-Risk Severe AS
The Lesson: TAVI is non-inferior—and in specific platforms superior—to SAVR for the composite of death, stroke, or rehospitalization at early follow-up in low-risk patients.
Key Findings: Low 30-day and 1-year mortality and stroke rates with rapid functional recovery compared to open surgery.
Viva Q&A:
Q: What critical considerations govern TAVI decision-making in young, low-risk patients?
A: Valve durability beyond 10–15 years, future re-access to coronary ostia, lifetime management (TAVI-in-TAVI vs. SAVR first), and the incidence of new permanent pacemaker implantation.
43. COAPT (2018): Transcatheter Edge-to-Edge Repair (TEER) in Secondary MR
The Lesson: Transcatheter edge-to-edge repair (MitraClip) added to maximal GDMT improves survival and drastically cuts hospitalizations in selected secondary (functional) MR.
Key Findings: 47% reduction in HF hospitalizations and a 38% reduction in all-cause mortality at 24 months.
Viva Q&A:
Q: What defined the optimal responders in COAPT?
A: Disproportionate MR: severe mitral regurgitation (effective regurgitant orifice area EROA ≥ 30-40 mm²) relative to a moderately dilated, non-exhausted left ventricle (LVESD ≤ 70 mm, LVEF 20–50%).
44. MITRA-FR (2018): MitraClip in Severe Secondary MR
The Lesson: Percutaneous mitral valve repair does not improve mortality or HF hospitalizations when severe LV dilatation exceeds the degree of functional MR.
Key Findings: No significant difference in 12-month mortality or heart failure hospitalizations between MitraClip plus GDMT vs. GDMT alone.
Viva Q&A:
Q: Why did MITRA-FR fail while COAPT succeeded?
A: MITRA-FR enrolled patients with proportionate MR—massive LV end-diastolic volumes where severe cardiomyopathy was the primary driver of prognosis and MR was largely a secondary bystander.
F. CARDIOVASCULAR PREVENTION & PHARMACOTHERAPY
45. HOPE (2000): Ramipril in High-Risk Cardiovascular Disease
The Lesson: Tissue-protective ACE inhibition with Ramipril prevents major atherothrombotic events in high-risk patients with preserved LV ejection fraction.
Key Findings: 22% reduction in the composite of CV death, MI, or stroke in patients with established vascular disease or diabetes plus one additional risk factor.
Viva Q&A:
Q: Did the blood pressure reduction fully account for the clinical benefits in HOPE?
A: No; the modest 3/2 mmHg BP reduction did not fully explain the large outcome reduction, highlighting direct vasculoprotective and anti-atherosclerotic effects.
46. ASCOT-BPLA (2005): Modern vs. Traditional Antihypertensive Regimens
The Lesson: A modern Amlodipine ± Perindopril regimen is clinically superior to an Atenolol ± Thiazide regimen in preventing CV events and all-cause mortality.
Key Findings: Significant reductions in all-cause mortality, fatal and non-fatal stroke, and new-onset diabetes.
Viva Q&A:
Q: Why did the Atenolol-based regimen underperform despite similar brachial cuff pressures?
A: Atenolol is ineffective at lowering central aortic systolic pressure and augments central pulse wave reflection compared to vasodilating CCB/ACEi therapy.
47. REDUCE-IT (2019): Icosapent Ethyl in Persistent Hypertriglyceridemia
The Lesson: High-dose, purified Eicosapentaenoic Acid (Icosapent Ethyl 4 g/day) significantly reduces ischemic events in statin-treated patients with elevated triglycerides (135–499 mg/dL).
Key Findings: 25% relative risk reduction in major adverse cardiovascular events (MACE), including a 20% reduction in cardiovascular death.
Viva Q&A:
Q: Can generic over-the-counter mixed omega-3 fatty acid supplements achieve the same outcome?
A: No; broad mixed EPA/DHA trials (e.g., STRENGTH) failed to show benefit, confirming that only high-dose purified ethyl ester of EPA possesses unique membrane-stabilizing and anti-atherothrombotic properties.
48. DASH (1997): Dietary Approaches to Stop Hypertension
The Lesson: A diet rich in fruits, vegetables, and low-fat dairy with reduced saturated fat and sodium significantly lowers systemic blood pressure.
Key Findings: SBP reductions of 5.5 to 11.4 mmHg in hypertensive individuals, equivalent to monotherapy pharmacotherapy.
Viva Q&A:
Q: What micronutrient profile makes the DASH diet effective?
A: High dietary potassium, magnesium, and calcium intake combined with restricted sodium intake.
49. CAST (1989): Cardiac Arrhythmia Suppression Trial
The Lesson: Suppression of asymptomatic/mild ventricular ectopy with Class 1C antiarrhythmics (Flecainide, Encainide) post-myocardial infarction paradoxically increases mortality.
Key Findings: Trial terminated early due to a greater than twofold increase in arrhythmic deaths in the active drug arms.
Viva Q&A:
Q: What enduring clinical rule was born from CAST?
A: "Suppression of a surrogate marker (PVC count on Holter) does not equal reduction in hard endpoints (sudden cardiac death)." Proarrhythmia in scarred, ischemic myocardium is lethal.
THE EXAM-HALL VIVA PROTOCOL
Anchor in the Core Lesson: When an examiner asks for trial evidence, avoid starting with sample sizes or p-values. Deliver the Practice-Changing Lesson first, then detail the specific inclusion criteria and hard endpoints.
Master the Shift in Care: Always know what standard practice was before the trial versus after the trial (e.g., CONSENSUS changing heart failure from inotropic support to neurohormonal blockade).
Integrate ABCDE First: If an examiner presents an unstable, deteriorating patient during a case presentation, execute resuscitation and stabilization protocols first. Bring in landmark evidence once the acute emergency is stabilized to formulate the definitive secondary prevention plan.
Comments
Post a Comment
Join the academic discussion. Share your clinical insights, questions, or perspectives below.